KOREA WHO
-
-
Chairman and CEO of Mezzion
Park Dong-hyun
Wall Street Veteran Eyes Third FDA Bid After 20 Years
-
Last Updated on May 23, 2026
-
Chairman and CEO of Mezzion
Copy Url : https://www.koreawho.com/profile/ParkDonghyun- Life Summary
Park Dong-hyun is chairman and CEO of Mezzion.
He faces the urgent task of securing financial stability amid concerns over capital impairment.
He was born on August 15, 1956.
He graduated from Yale University in the United States with a degree in economics and earned a master’s degree in accounting from New York University’s business school. He completed an MBA program at Stanford Graduate School of Business.
He worked as a manager in the corporate audit division of KPMG in the United States and as a director in Merrill Lynch’s investment banking group. After returning to Korea, he founded Feist Investment and advised on corporate mergers and acquisitions.
After serving as an outside director of Dong-A Pharmaceutical, he was recruited in 2002 as CEO of Dong-A PharmTech, Dong-A Pharmaceutical’s new drug development subsidiary. After increasing his stake, he reorganized the company into Mezzion in 2013 and became chairman and CEO.
He transformed himself from a finance and corporate M&A expert from Wall Street in New York into the head of a drug development company.
He is focusing his capabilities on switching the indication of udenafil, developed as an erectile dysfunction treatment, to develop it as a treatment for Fontan patients.
#ParkDonghyun #Mezzion #CEO #drugdevelopment #udenafil #Fontanpatients #DongAPharmTech #DongAPharmaceutical #WallStreet #biopharmaceuticals
He faces the urgent task of securing financial stability amid concerns over capital impairment.
He was born on August 15, 1956.
He graduated from Yale University in the United States with a degree in economics and earned a master’s degree in accounting from New York University’s business school. He completed an MBA program at Stanford Graduate School of Business.
He worked as a manager in the corporate audit division of KPMG in the United States and as a director in Merrill Lynch’s investment banking group. After returning to Korea, he founded Feist Investment and advised on corporate mergers and acquisitions.
After serving as an outside director of Dong-A Pharmaceutical, he was recruited in 2002 as CEO of Dong-A PharmTech, Dong-A Pharmaceutical’s new drug development subsidiary. After increasing his stake, he reorganized the company into Mezzion in 2013 and became chairman and CEO.
He transformed himself from a finance and corporate M&A expert from Wall Street in New York into the head of a drug development company.
He is focusing his capabilities on switching the indication of udenafil, developed as an erectile dysfunction treatment, to develop it as a treatment for Fontan patients.
#ParkDonghyun #Mezzion #CEO #drugdevelopment #udenafil #Fontanpatients #DongAPharmTech #DongAPharmaceutical #WallStreet #biopharmaceuticals
- Life Summary
- Career Highlights & Challenges
- · Rising Funding Burden Amid Prolonged Trials
- · Udenafil FUEL-2 Redesign and FDA Rechallenge
- · Udenafil’s Shift From ED Drug to Rare Heart Disease Treatment
- · Pursuing Expansion Into ADPKD Treatment
- · Derivative Losses Deepen Net Deficit, Raise Capital Concerns
- · Strengthening Udenafil Patents and Disease Codes
- · Pursuing Expansion Into Europe
- · Started as Dong-A Pharmaceutical Subsidiary, Later Listed on Kosdaq
- · From Wall Street to Drug Development
- · Mezzion’s Governance Structure
- · Mezzion’s Journey
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Family & Personal Connections
- Additional Information
- Notable Quotations
- Infographic & Photos